Sorafenib

For research use only. Not for use in humans.

Catalog No.S7397 Synonyms: BAY 43-9006

206 publications

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Sorafenib has been cited by 206 publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnMXmtkUUN3ME2wMlAxODByM{CzJO69VQ>? NXHwd5FKW0GQR1XS
MONO-MAC-6 M1LZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEC0NVgh|ryP MXvTRW5ITVJ?
ALL-PO NFL6R2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnuxTWM2OD1yLkCzNVg1KM7:TR?= MnPwV2FPT0WU
NKM-1 NXnOSZVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfXOGhDUUN3ME2wMlA4PDF4IN88US=> M4H0e3NCVkeHUh?=
CGTH-W-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrDOpZKSzVyPUCuNlUxOjJizszN MlLWV2FPT0WU
BB65-RCC NFThXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[ydIU2UUN3ME2wMlQ4ODd|IN88US=> Ml7VV2FPT0WU
NOS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwNU[zOkDPxE1? MXrTRW5ITVJ?
SH-4 NFXufpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;sTWM2OD1yLk[1OlE{KM7:TR?= MWTTRW5ITVJ?
HOP-62 NGnRe3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK2TWM2OD1yLki1NFg5KM7:TR?= NWT3XYZ6W0GQR1XS
HCC2998 NH3GOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG0fZJ2UUN3ME2wMlg5QDF6IN88US=> MXnTRW5ITVJ?
GDM-1 NXLkfIw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzWenJKSzVyPUCuPVA3QThizszN M4K4NnNCVkeHUh?=
KM12 NGPEXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXpSHNKSzVyPUGuNFIxQThizszN MoLDV2FPT0WU
LB2518-MEL NUH3d|JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHBZmNOUUN3ME2xMlIxQDB7IN88US=> MkfXV2FPT0WU
NCI-H1436 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP3SnV5UUN3ME2xMlIyPjd6IN88US=> MoGxV2FPT0WU
EM-2 M3zqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TJVmlEPTB;MT6zOVU4QCEQvF2= NXXyV2x{W0GQR1XS
LAMA-84 NEnj[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHzbJZsUUN3ME2xMlM4PjR6IN88US=> MoXzV2FPT0WU
KG-1 NXftVmV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jN[2lEPTB;MT60O|k{PSEQvF2= M{jLOHNCVkeHUh?=
A388 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PUU2lEPTB;MT61PVE3PSEQvF2= M2i5NXNCVkeHUh?=
no-10 NVW2PVNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;ZcIw6UUN3ME2xMlYyPzJ4IN88US=> M{fVS3NCVkeHUh?=
SF126 NEnlfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwNkO4NVIh|ryP NIXZPYhUSU6JRWK=
MEG-01 MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrj[plOUUN3ME2xMlgxQThizszN MnvlV2FPT0WU
A3-KAW MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXBTWM2OD1zLki4OFIh|ryP MWHTRW5ITVJ?
D-247MG MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDoUGhKSzVyPUKuNVQ1QCEQvF2= NGPyV3VUSU6JRWK=
OVCAR-4 MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzvTWM2OD1{LkKxN|k{KM7:TR?= M1zNUXNCVkeHUh?=
NCI-SNU-1 NF3JfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHnc|FzUUN3ME2yMlMyPjJizszN MUHTRW5ITVJ?
NCI-H2171 M4DJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJwM{m3OlQh|ryP MmrWV2FPT0WU
SIG-M5 NUTyXVVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHmXGlKSzVyPUKuOFIzPDJizszN NXO0eWozW0GQR1XS
BE-13 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPwcJhmUUN3ME2yMlY6PjB7IN88US=> NFfHe2hUSU6JRWK=
K052 NEPJVGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13RUmlEPTB;Mj63OFYyPiEQvF2= Mm\NV2FPT0WU
L-540 MlzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPib4tKSzVyPUKuO|U4QDlizszN MVnTRW5ITVJ?
KMOE-2 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwOEGzOUDPxE1? NIXIXW9USU6JRWK=
MFH-ino MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;5bZpKSzVyPUKuPVIyQDVizszN MXvTRW5ITVJ?
HL-60 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfkVmsyUUN3ME2zMlA3Ojl7IN88US=> M3\BcHNCVkeHUh?=
HCC2218 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HU[WlEPTB;Mz6xNlAxOyEQvF2= M36yNnNCVkeHUh?=
TE-5 MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\XTWM2OD1|LkGzNVYzKM7:TR?= MXrTRW5ITVJ?
MZ1-PC Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe4eFRQUUN3ME2zMlQ4PTB7IN88US=> NH;EeoNUSU6JRWK=
MRK-nu-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVThelYyUUN3ME2zMlYyPDZ6IN88US=> M4S5UHNCVkeHUh?=
MZ7-mel MnzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfPdlFzUUN3ME2zMlY3ODl7IN88US=> Mn[2V2FPT0WU
BC-1 M{HJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTNwN{SwNkDPxE1? M1fwOnNCVkeHUh?=
ST486 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTNwOEO2O|Mh|ryP M3vlcnNCVkeHUh?=
KS-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHMTWM2OD1|Lki4NVk5KM7:TR?= NHG0NWtUSU6JRWK=
SK-NEP-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml63TWM2OD12LkG2PFE2KM7:TR?= NYTxWXo2W0GQR1XS
BC-3 M164NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XYSWlEPTB;ND6yN|M6OSEQvF2= NWiwXWJEW0GQR1XS
NCI-H1581 NFrqNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ocWlEPTB;ND6yPFc6QCEQvF2= MVnTRW5ITVJ?
MHH-PREB-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mon2TWM2OD12LkSwOFg1KM7:TR?= M3[yS3NCVkeHUh?=
NOMO-1 NEH6UnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jIOmlEPTB;ND60PFkxPSEQvF2= MkDVV2FPT0WU
QIMR-WIL NXL3NmgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDETWM2OD13LkC3Nlk1KM7:TR?= NX3HRY1sW0GQR1XS
SF539 NWTuTmtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXUTWM2OD13LkGzNlI4KM7:TR?= NV7JO3FYW0GQR1XS
TE-12 NYT6SIxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2KyUGlEPTB;NT6yOFkzQSEQvF2= M1ToTXNCVkeHUh?=
NCI-H510A NHjFN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHURYxKSzVyPUWuOFE3QDVizszN MV;TRW5ITVJ?
JAR M4jkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;ZTWM2OD13LkWwPFI1KM7:TR?= NY\UeFZIW0GQR1XS
no-11 NIrVUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHvZotKSzVyPUWuO|M2PjhizszN MkTvV2FPT0WU
BV-173 Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTVwOUW2PFIh|ryP NULWb5dKW0GQR1XS
SR NIr3XnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDETWM2OD14LkCwOlc5KM7:TR?= MoC4V2FPT0WU
MOLT-16 M2\GW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PXOGlEPTB;Nj6yOVI3PiEQvF2= M1n5THNCVkeHUh?=
MZ2-MEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LWUGlEPTB;Nj6zNVg{QSEQvF2= MXTTRW5ITVJ?
SW954 NIm1W3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXuRWdKSzVyPU[uOFU5PjZizszN NHy3eJBUSU6JRWK=
ML-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTZwNUK4OFkh|ryP MYDTRW5ITVJ?
OCI-AML2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnUWHJIUUN3ME22MlYyODZ{IN88US=> MXTTRW5ITVJ?
SIMA MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETxU5NKSzVyPUeuNFAyODFizszN MlrmV2FPT0WU
DOHH-2 M1PnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTdwMEW2O|Yh|ryP NIC0[YJUSU6JRWK=
697 M2DqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nyVmlEPTB;Nz6wOVk5QSEQvF2= MUnTRW5ITVJ?
NB1 M2PISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjJfIFOUUN3ME23MlQxPDB5IN88US=> NGXFN25USU6JRWK=
D-392MG NWPRS3ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fNZmlEPTB;Nz62NlY3OyEQvF2= NFXTOIlUSU6JRWK=
ES8 M1S0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq2SmxKSzVyPUeuO|Y2ODNizszN MUDTRW5ITVJ?
RPMI-8226 MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTdwOES1NVEh|ryP MX\TRW5ITVJ?
IST-MEL1 M4njfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LLT2lEPTB;OD60NFAxOiEQvF2= NFu2TWpUSU6JRWK=
NB14 NYrS[pdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33YZ2lEPTB;OD62N|E{OyEQvF2= MoezV2FPT0WU
HD-MY-Z NVTiUVh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DyOWlEPTB;OD62N|c1PiEQvF2= MWLTRW5ITVJ?
TE-10 NIHVZ|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvsTWM2OD16Lke2N|U{KM7:TR?= M2PvfnNCVkeHUh?=
LC-1F MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjRPYNuUUN3ME25MlExQDN2IN88US=> NWG4TYg{W0GQR1XS
OS-RC-2 M4KwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHhTWM2OD17LkGxNlQ{KM7:TR?= NXzhU29TW0GQR1XS
NCI-SNU-16 NUm3XmtMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\l[5pKSzVyPUmuNlExOjZizszN MWXTRW5ITVJ?
SHP-77 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XvfWlEPTB;OT63NVY3OiEQvF2= NHL0XXlUSU6JRWK=
A4-Fuk NF7JfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjmTWM2OD17Lke1OlEh|ryP MWrTRW5ITVJ?
NB6 M{PYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DYSWlEPTB;OT63OlAzQSEQvF2= NHW1TGtUSU6JRWK=
JiyoyeP-2003 NVzSVWN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm4OYlKSzVyPUGwMlQ4PDVizszN NITsdmxUSU6JRWK=
DMS-114 MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFyLkW0OFEh|ryP MoHpV2FPT0WU
NB7 NVPO[G1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofZTWM2OD1zMD63OVI3KM7:TR?= MnTqV2FPT0WU
NCI-H747 NIS5UI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PxUGlEPTB;MUGuNVIyPiEQvF2= MnmwV2FPT0WU
HH MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPnb41kUUN3ME2xNU4{QDd4IN88US=> MXrTRW5ITVJ?
EW-18 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFzLkmwOFQh|ryP Mnj0V2FPT0WU
CHP-126 NXj4SlQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD3SZBDUUN3ME2xNU46PzN6IN88US=> MVjTRW5ITVJ?
NTERA-S-cl-D1 NEPFeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nLUmlEPTB;MUKuNFI4QCEQvF2= M4\WPXNCVkeHUh?=
DEL NGexN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvrS2FKSzVyPUGyMlA6QDVizszN M2\vVnNCVkeHUh?=
LU-139 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HG[2lEPTB;MUKuOVQyOyEQvF2= M4PjbXNCVkeHUh?=
P30-OHK NID4TIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITJcWJKSzVyPUGyMlU1PzlizszN MXzTRW5ITVJ?
NCI-H1522 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrZTWM2OD1zMj63OFYh|ryP NVHF[YMxW0GQR1XS
NCI-H1299 NVHhZZdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLo[XpKSzVyPUGzMlI6OTFizszN MmPhV2FPT0WU
UACC-257 MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M320[GlEPTB;MUOuOVEzPiEQvF2= NGL3dndUSU6JRWK=
Calu-6 NHvGdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3SVGgxUUN3ME2xN{43ODR4IN88US=> NXfCOFljW0GQR1XS
NCI-H1882 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGySppKSzVyPUGzMlg2PTVizszN MmHuV2FPT0WU
BB30-HNC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v2UmlEPTB;MUSuNFYxQSEQvF2= NXuwXZNIW0GQR1XS
ES1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[3TWM2OD1zND6xOVUyKM7:TR?= NWXm[GhkW0GQR1XS
NCI-H1694 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi3U|VqUUN3ME2xOE41QDFzIN88US=> NVTzfoVbW0GQR1XS
IST-SL1 NELtd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDxNoJKSzVyPUG0Mlk3OTZizszN NVzvfVVZW0GQR1XS
ECC4 M{DyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXuTWM2OD1zNT6wOVU5KM7:TR?= MWXTRW5ITVJ?
MDA-MB-134-VI NWj4eZh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXjTWM2OD1zNT60NVMyKM7:TR?= NFHoZmxUSU6JRWK=
SCH MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVj5cpp5UUN3ME2xOU41PzJ6IN88US=> MnrQV2FPT0WU
SK-N-FI M2To[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPDZpRGUUN3ME2xOU43PTN2IN88US=> MXPTRW5ITVJ?
HDLM-2 M4jZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\BTWM2OD1zNj6wO|E1KM7:TR?= NEOxcJNUSU6JRWK=
Ramos-2G6-4C10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\MXWlEPTB;MU[uNVI6PyEQvF2= NWDN[4JJW0GQR1XS
EW-24 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDpTWM2OD1zNj6xOlYyKM7:TR?= MXHTRW5ITVJ?
NCI-H2141 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfFbXZKSzVyPUG2MlE5QSEQvF2= MUPTRW5ITVJ?
LC4-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TIb2lEPTB;MU[uOlEyQSEQvF2= NFv5SotUSU6JRWK=
HT-144 NITRbHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvQT|R[UUN3ME2xO{4xODZizszN M37EbXNCVkeHUh?=
SK-MEL-1 NInrZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDrZYFCUUN3ME2xO{4xODd{IN88US=> MXvTRW5ITVJ?
SCC-15 M3fLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTF5LkG2N|gh|ryP NHn4[lJUSU6JRWK=
C8166 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\RTWM2OD1zNz62PFM{KM7:TR?= NHf4bZpUSU6JRWK=
GOTO MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPRTWM2OD1zNz64N|Q1KM7:TR?= M4i2dnNCVkeHUh?=
COR-L279 NGTZdHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF6LkGzOlIh|ryP NVfmN3gzW0GQR1XS
K-562 M1XJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF6LkexOFMh|ryP NXjBRo5PW0GQR1XS
ES3 NHLHb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDVNG91UUN3ME2xPE45ODRzIN88US=> MXvTRW5ITVJ?
LU-165 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTGcIZKSzVyPUG5MlcxODhizszN NYnxNIw{W0GQR1XS
KM-H2 MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPCTWM2OD1{MD6zNVg1KM7:TR?= NHiwOHpUSU6JRWK=
RL NGn6dnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorLTWM2OD1{MD65OlkzKM7:TR?= MnH3V2FPT0WU
EW-3 M{DYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jSZWlEPTB;MkGuNVg5QSEQvF2= MY\TRW5ITVJ?
A101D M3XjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjnb2pKSzVyPUKxMlM4PTJizszN M{\hSXNCVkeHUh?=
HUTU-80 NVO0fI1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJzLkO5OFYh|ryP M2i1WXNCVkeHUh?=
NCI-H23 NVv2SndRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXPflFKSzVyPUKxMlM6QTJizszN NH[xZohUSU6JRWK=
PF-382 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXZTWM2OD1{MT60OFA{KM7:TR?= NGC5NFRUSU6JRWK=
LB373-MEL-D NVn1epZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHpTWM2OD1{MT61OlE2KM7:TR?= NVXaeYptW0GQR1XS
TE-8 M1jtO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTJzLk[zPVQh|ryP Mnf0V2FPT0WU
TE-9 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf4TWM2OD1{MT64OVE{KM7:TR?= NGXLcGJUSU6JRWK=
Daudi MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP1em9KSzVyPUKxMlk{ODRizszN M4LCdXNCVkeHUh?=
D-542MG NGrSfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvlTWM2OD1{Mj6wNlU3KM7:TR?= M1nOTXNCVkeHUh?=
U-698-M M2K2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJ{LkS2NFMh|ryP MlK3V2FPT0WU
ES6 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDhSItKSzVyPUKyMlc{PjZizszN NYnWN2F[W0GQR1XS
DU-4475 NVfVdFY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXITWM2OD1{Mz64PFk4KM7:TR?= NWrRUXJbW0GQR1XS
ECC12 M3vBWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrrbHVKSzVyPUK0MlI5ODNizszN NGHYXmZUSU6JRWK=
C2BBe1 NUf2dI53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fY[mlEPTB;MkSuN|I{QSEQvF2= NWO0O4xwW0GQR1XS
IST-SL2 M1nBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\JTWM2OD1{ND60N|YzKM7:TR?= NEfsZnpUSU6JRWK=
DJM-1 MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ2LkWyNlEh|ryP NYLHe2ltW0GQR1XS
DMS-153 MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnEU25NUUN3ME2yOE45PjF2IN88US=> NITDZ3VUSU6JRWK=
NB13 NUjUOFJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ3LkCyOlUh|ryP MYLTRW5ITVJ?
SK-N-DZ MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;OTWM2OD1{Nj6zOFE1KM7:TR?= NYrsbZRpW0GQR1XS
COR-L88 NHi0fI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\XTWM2OD1{Nj61O|k3KM7:TR?= NWLQOm1tW0GQR1XS
LU-65 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ4Lki1N|Uh|ryP NVX0[4pvW0GQR1XS
TGBC1TKB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTJ4Lkm4Nlgh|ryP MVrTRW5ITVJ?
THP-1 Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ5LkKxOFEh|ryP Ml3GV2FPT0WU
ONS-76 NXnYcnZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3NXolCUUN3ME2yO{4{OzJizszN NEC1VWFUSU6JRWK=
LC-2-ad Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHZ[mtKSzVyPUK3MlYzOzFizszN M{jLR3NCVkeHUh?=
EW-13 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPUTWM2OD1{OT6xO|Q3KM7:TR?= NYjOVYZ1W0GQR1XS
MS-1 NFnDZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTNyLkeyO|gh|ryP NFL1XoFUSU6JRWK=
NCI-H2227 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTNyLkm4NFYh|ryP NVzPNpVIW0GQR1XS
LXF-289 NWDvTnVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX60eYxtUUN3ME2zNU41PDl{IN88US=> Mn[yV2FPT0WU
MC116 NFn5OVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXXTWM2OD1|Mj6wPFI3KM7:TR?= NF3JbXJUSU6JRWK=
EVSA-T MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LzOmlEPTB;M{KuNlU5PSEQvF2= NGf1O|ZUSU6JRWK=
CTB-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;TU2lEPTB;M{OuNVExOSEQvF2= NF\McFdUSU6JRWK=
COLO-320-HSR M3X2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPhbVhKSzVyPUOzMlE3ODNizszN M3LQe3NCVkeHUh?=
NCI-H2196 NISxbHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzGSppKSzVyPUOzMlI2PTdizszN NHHNfmRUSU6JRWK=
LB2241-RCC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT5cWZGUUN3ME2zN{4{OTN3IN88US=> Mme1V2FPT0WU
LS-513 NVq1U4RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXhTWM2OD1|Mz64OlM5KM7:TR?= NEXFNFVUSU6JRWK=
LP-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jXWGlEPTB;M{OuPVk2PiEQvF2= Moj0V2FPT0WU
A253 NEDRbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTN2LkKyPVYh|ryP M{XEU3NCVkeHUh?=
SK-MM-2 NUGzXnhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1mxPWlEPTB;M{SuPVQ2OSEQvF2= M1W1d3NCVkeHUh?=
NCI-H1963 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrTTWM2OD1|NT6zNFczKM7:TR?= MXfTRW5ITVJ?
MMAC-SF NX;rNopPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN3Lki3PFUh|ryP M4W1SnNCVkeHUh?=
LB831-BLC M{TNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTQcFJxUUN3ME2zOk4xPjV2IN88US=> NF\xTIpUSU6JRWK=
WSU-NHL Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzXT48xUUN3ME2zOk4yPjRizszN NXjr[mEzW0GQR1XS
CESS MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LNZWlEPTB;M{[uNlg1QCEQvF2= MW\TRW5ITVJ?
NEC8 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTN4LkW4N|Uh|ryP NWj4PWhJW0GQR1XS
KNS-42 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4KzUGlEPTB;M{euNVI{PyEQvF2= NYPPdmpSW0GQR1XS
MHH-CALL-2 NF3VXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTN5LkG4NlEh|ryP Mk\BV2FPT0WU
K5 MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTN6LkSzJO69VQ>? NYj1ZXdJW0GQR1XS
CP66-MEL MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGezZZJKSzVyPUO5MlA4OzNizszN NF:5dWtUSU6JRWK=
OPM-2 MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\ofFBKSzVyPUO5Mlg1OzJizszN M4DpeHNCVkeHUh?=
IST-MES1 NH:1PZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTRyLkOwPVYh|ryP MX\TRW5ITVJ?
EC-GI-10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Dv[WlEPTB;NEGuOVgxPSEQvF2= MXjTRW5ITVJ?
CTV-1 NXzMU2JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzUTWM2OD12Mj64OFA3KM7:TR?= NVG2OXVKW0GQR1XS
DG-75 Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TQ[WlEPTB;NEOuO|U6PSEQvF2= MXnTRW5ITVJ?
KNS-81-FD NHe2T|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml61TWM2OD12NT60NFU5KM7:TR?= NUHIWGY4W0GQR1XS
NCI-H82 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTR3LkW3OVgh|ryP NHfRUlBUSU6JRWK=
RPMI-8866 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1ztSGlEPTB;NE[uNVg4OyEQvF2= MV7TRW5ITVJ?
ACN MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HSdGlEPTB;NE[uOFM1KM7:TR?= M4TaWXNCVkeHUh?=
NCI-H1395 NUj0fVNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33uUWlEPTB;NE[uOFc2PiEQvF2= MXPTRW5ITVJ?
NCI-H209 NH74N2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES5N3BKSzVyPUS3MlE1ODVizszN NIT1boJUSU6JRWK=
TGW MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHyTWM2OD12OT6wO|kyKM7:TR?= NHvabFFUSU6JRWK=
NCI-H748 NFXF[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR7LkS3OVMh|ryP M3nVPXNCVkeHUh?=
EKVX MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrsTWM2OD12OT62OlI5KM7:TR?= NIP4ZodUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3-I / LC-3II / ATG5; 

PubMed: 23392173     


Sorafenib induces the conversion of LC3 in a dose-dependent manner. PLC5, Hep3B, SK-Hep1 and HepG2 were exposed to sorafenib at the indicated doses for 16 h and the expression levels of LC3-II were analyzed by western blot.

p-STAT3 / STAT3 / Mcl-1; 

PubMed: 23392173     


Effects of sorafenib on STAT3-related proteins in HCC cells. The cells were treated with sorafenib at the indicated dose for 16 h. 

β-catenin / Survivin / Mcl-1 / PTMA; 

PubMed: 26517516     


Co-inhibition of β-catenin and PTMA by sorafenib in HCC cells. Cell lines indicated on top were treated or not with 10 μM sorafenib for 24 hrs and processed for immuno-blotting. IC50 values (the concentration of sorafenib that inhibits 50% of cell growth) for each cell line are indicated below the panels.

pERK / ERK; 

PubMed: 22286758     


Western blot analysis of p-ERK (T202/Y204) and ERK at indicated time points in HCT116 cells treated with 20 μmol/L sorafenib.

p-PKM2(y105) / PMK2 / Caspase-9; 

PubMed: 26959741     


Sorafenib downregulates the p-PKM2 (Y105) at the indicated doses after treatment for 24 h.

RET(pY1016) / VEGFR2(pY1214) / MEK1(pT292) / ERK(pY204); 

PubMed: 22941289     


Sorafenib affected the phosphorylation of receptor tyrosine kinase RET and VEGFR2, as well as MEK/ERK kinases signaling cascades in three cell lines. Three cell lines were treated by sorafenib with two concentration gradients, 1 and 5 μmol/L/L, and then collected after 2, 4, and 8 h, cells without sorafenib treatment were as the controls (0 h). Total proteins were extracted and quantified to be used in Western blot assays. (A) Sorafenib inhibited RET and VEGFR2 phosphorylation dose-dependently while activated MEK and ERK phosphorylation in A549 cells. (B) Sorafenib also inhibited RET and VEGFR2 phosphorylation, and slightly activated MEK and ERK phosphorylation in HeLa cells. (C) Sorafenib activated the phosphorylation of RET, VEGFR2, and MEK, but inhibited ERK phosphorylation in HepG2 cells.

Cyclin D1; 

PubMed: 26039995     


Dose-escalation effects of sorafenib or SC-1 for 24 h on STAT3-related proteins in HSC-T6 and LX2 cells.

23392173 26517516 22286758 26959741 22941289 26039995
Growth inhibition assay
Cell viability; 

PubMed: 26039995     


Dose-escalation and time-dependent effects of sorafenib for 24 or 48 h on cell viability in HSC-T6, LX2, and mouse primary HSCs. Circles, mean; bars, SE (n = 3).

26039995
Immunofluorescence
p65; 

PubMed: 22286758     


HCT116 cells were treated with 20 μmol/L sorafenib or 10 ng/mL TNF-α for 3 hours then fixed. Immunofluorescence was carried out as described in the Materials and Methods for p65 (green) and DAPI (blue). Representative pictures (400×) are shown.

cytochrome c; 

PubMed: 22278289     


Immunoflourescent staining and quantification of mitochondrial membrane potential (appearing in red, mitotracker) and cytochrome c (appearing in green, FITC) in 22Rv1 and PC3 treated with 20 μM sorafenib for 24 h.

22286758 22278289
ELISA
TGF-beta / CD206; 

PubMed: 26158762     


In Macrophage, TGF-β secretion and CD206 were confirmed by ELISA.

Caspase-9 / Caspase-3; 

PubMed: 30923462     


Caspase-9 and caspase-3 activities were measured via ELISA assay. FCCP, an activator of mitophagy, was added into the medium of sorafenib-treated cells to activate mitophagy. Adenovirus-loaded LATS2 (Ad-LATS2) was transfected into HepG2 cells in the presence of sorafenib. *p < 0.05 vs. control group; #p < 0.05 vs. Sorafenib + Ad-cont group; #p < 0.05 vs. Sorafenib + Ad-LATS2 group.

26158762 30923462
In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

- Collapse
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Formulation: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL warmed (135.53 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 400+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
in solvent
Synonyms BAY 43-9006
Smiles CNC(=O)C1=CC(=CC=N1)OC2=CC=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000737 Not yet recruiting Drug: YIV-906+Sorafenib|Drug: Placebo+Sorafenib Advanced Hepatocellular Carcinoma Yiviva Inc. August 15 2019 Phase 2
NCT03958669 Not yet recruiting -- Hepatocellular Carcinoma|Sorafenib University Hospital Tuebingen|German Federal Ministry of Education and Research July 1 2019 --
NCT03764293 Not yet recruiting Drug: SHR-1210|Drug: Apatinib|Drug: Sorafenib Locally Advanced or Metastatic and Unresectable HCC Jiangsu HengRui Medicine Co. Ltd. January 2019 Phase 3
NCT03582618 Recruiting Drug: Sorafenib|Drug: CVM-1118 Hepatocellular Carcinoma|Advanced Cancer TaiRx Inc. July 12 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID